{"entity":{"id":"tng260","kind":"drug","name":"TNG260","aka":[],"tldr":"TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","summary":"TNG260 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Tango Therapeutics, Inc., in non-small-cell lung cancer, small-cell lung cancer. Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of TNG260","url":"https://clinicaltrials.gov/search?intr=TNG260"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tango-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05887492"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"TNG260","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tng260/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/"}],"trial":[{"id":"nct05887492","kind":"trial","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","route":"/trials/nct05887492/"}]}}